Comparative Pharmacology
Head-to-head clinical analysis: DIENESTROL versus ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIENESTROL versus ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST.
DIENESTROL vs ESTRADIOL VALERATE; ESTRADIOL VALERATE; DIENOGEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to effects similar to endogenous estrogens.
Estradiol valerate is a prodrug of estradiol, an estrogen receptor agonist. Dienogest is a progestin with partial antiandrogenic activity, acting as a progesterone receptor agonist with antiovulatory and endometrial antiproliferative effects.
0.1 to 0.5 mg orally once daily for estrogen replacement therapy; 0.5 to 1.0 mg orally once daily for prostatic carcinoma.
One tablet daily containing estradiol valerate 2 mg and dienogest 3 mg (oral).
None Documented
None Documented
Terminal elimination half-life is approximately 24-48 hours, longer with hepatic impairment.
Clinical Note
moderateDienestrol + Etoricoxib
"Dienestrol may increase the thrombogenic activities of Etoricoxib."
Clinical Note
moderateDienestrol + Parecoxib
"Dienestrol may increase the thrombogenic activities of Parecoxib."
Clinical Note
moderateDienestrol + Voriconazole
"The metabolism of Voriconazole can be decreased when combined with Dienestrol."
Clinical Note
moderateDienestrol + Lumiracoxib
"Dienestrol may increase the thrombogenic activities of Lumiracoxib."
Estradiol valerate: Terminal half-life is approximately 13-14 hours for estradiol. Dienogest: Terminal half-life is about 10-11 hours. The combination allows for once-daily dosing with sustained hormone levels.
Primarily renal (40-60% as glucuronide conjugates) and biliary/fecal (30-50% with enterohepatic recycling).
Estradiol valerate and dienogest: Urinary excretion accounts for approximately 50-60% of total clearance, primarily as glucuronide conjugates of estradiol and dienogest metabolites. Fecal/biliary excretion accounts for 30-40% of dienogest and its metabolites. For estradiol valerate, about 30% of metabolites are excreted in bile and feces.
Category C
Category D/X
Estrogen
Estrogen